Thc

AHPA’s updated Hemp Lexicon seeks to shed light on ‘full spectrum’ question

25-Aug-2022 By Hank Schultz

The American Herbal Products Association has released a new guidance document that seeks to bring clarity to hemp nomenclature, in particular what ought to be meant by the terms ‘broad spectrum’ and ‘full spectrum’ extracts.

Provisions of Senate bill could decimate hemp industry, industry group asserts

10-Aug-2022 By Hank Schultz

Legislation currently in the Senate could burden the hemp industry by setting an unrealistically low level of allowable THC, an industry group has said.

Majority of CBD products tested in study found to have at least some THC

29-Jun-2022 By Hank Schultz

A new study that sampled dozens of commercially available CBD products found detectable THC levels in 64% of them. Some levels were high enough to approach therapeutic thresholds or to potentially trigger drug test failures.

EU introduces trade harmonisation for hemp seed market

28-Mar-2022 By Nicola Gordon-Seymour

The European Commission has finally agreed maximum THC limits for hemp seed products for the EU market, putting an end to internal market fragmentation.

European Council adopts 0.3% maximum THC levels

20-Dec-2021 By Kavitha Sivasubramaniam

The European Council has adopted the new Common Agricultural Policy (CAP), which restores tetrahydrocannabinol (THC) levels of hemp varieties back to 0.3%.

Edibles that look like candy: a different kind of scary this Halloween

25-Oct-2021 By Danielle Masterson

Two attorneys are sounding the alarm on cannabis edibles that look just like popular candy—concerned these friendly looking treats could get into the wrong hands.

How TreeHouse Biosciences is helping brands with its patented THC remediation technology

23-Aug-2021 By Danielle Masterson

Keeping the THC within bounds in full spectrum hemp extracts is creating an opportunity for a company that is offering a remediation service.

Folium Biosciences becomes latest US firm to submit CBD Novel Food application in UK

18-Mar-2021 By Will Chu

Folium Biosciences has become another US-based firm to submit a Novel Foods application to the UK for its cannabidiol (CBD)-based oil in response to the 31 March deadline set by the country’s food authority.

Cannabinoid conflict: “Scandal” of high THC content in CBD products slammed by industry

17-Mar-2020 By Will Chu

The side effects of cannabidiol (CBD) products are ‘most probably’ due to native THC contamination rather than by direct action of CBD or its chemical transformation, according to a German-led study.

EDITOR'S SPOTLIGHT: SCIENCE & REGULATION

FSAI issues updates to CBD food and supplement recall

26-Feb-2020 By Will Chu

The Food Safety Authority of Ireland (FSAI) has updated its recall of CBD-related foods and food supplements that have flagged up safety concerns due to the presence of delta‐9‐tetrahydrocannabinol or THC.

CBD industry hits back at FSAI survey findings and ‘broad-brush statements’

17-Feb-2020 By Will Chu

Retailers in the CBD space have expressed frustration at a recent survey, which finds products analysed breach food law with some posing as potential safety risks for consumers.

NIU’s Global Round-up: Probiotic popularity in Japan, Poland streamlines supplement notifications, and more

03-Feb-2020 By Stephen Daniells

What’s happened across the Nutra-verse over the past seven days? Stay on top of things with our weekly round-up of key news from across the globe.

Contaminated CBD products could lead to anti-doping ban, ESSNA warns

08-Nov-2019 By Shane Starling

Athletes using cannabidiol (CBD) products should be prepared for a very real risk they could fail anti-doping tests due to contamination of banned tetrahydrocannabinol (THC), ESSNA has warned.

Gulf in CBD product quality laid bare as calls for tighter controls amplify

01-Oct-2019 By Will Chu

A cannabidiol (CBD) manufacturer is calling for greater regulatory controls after independent analyses of 31 CBD-based products found varying levels of active ingredients as well as CBD-related labelling issues.

Pharma at home, supplements abroad: Bod Australia's twin strategy for CBD success underlined by new Tourette's trial

17-Apr-2019 By Cheryl Tay

CBD firm Bod Australia has embarked on a first-of-its-kind clinical trial on medical cannabis for Tourette syndrome patients, while continuing to expand its supplements business in countries with a more conducive regulatory environment than its home market.